Simvastatin inactivates β1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells

Cancer Science

Volumn 98, Issue 6, 2007, Pages 890-899

  Takeda, Ikuko ^a   Maruya, Shin Ichiro ^a   Shirasaki, Takashi ^a   Mizukami, Hiroki ^a   Takahata, Takenori ^a   Myers, Jeffrey N ^b   Kakehata, Seiji ^a   Yagihashi, Soroku ^a   Shinkawa, Hideichi ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BETA1 INTEGRIN; CASPASE 3; COMPLEMENTARY DNA; DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; PROTEIN P27; SIMVASTATIN; THYMIDYLATE SYNTHASE; FOCAL ADHESION KINASE 1; HYPOCHOLESTEROLEMIC AGENT; PTK2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ACTIN FILAMENT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CARCINOMA CELL; CELL ADHESION; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CYTOPLASM; DNA MICROARRAY; DNA SYNTHESIS; DOWN REGULATION; DRUG EFFICACY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE INACTIVATION; HEAD AND NECK CARCINOMA; METASTASIS POTENTIAL; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; UPREGULATION; WESTERN BLOTTING; CANCER INVASION; CELL CULTURE; CELL CYCLE G1 PHASE; DRUG EFFECT; HEAD AND NECK TUMOR; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ANTICHOLESTEREMIC AGENTS; ANTIGENS, CD29; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CELL PROLIFERATION; CELL SURVIVAL; FOCAL ADHESION KINASE 1; G1 PHASE; HEAD AND NECK NEOPLASMS; HUMANS; MEVALONIC ACID; NEOPLASM INVASIVENESS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SIMVASTATIN; TUMOR CELLS, CULTURED;

EID: 34247868147     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00471.x     Document Type: Article

References (43)

1. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoAreductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997; 32: 403-25.
2. 1 to multiple cell cycles by lovastatin. Cancer Res 1991; 51: 3602-9.
3. Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 2005; 26: 883-91.
4. Katano H, Pesnicak L, Cohen JI. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci USA 2004; 101: 4960-5.
5. Khanzada UK, Pardo OE, Meier C, Downward J, Seckl MJ, Arcaro A. Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signaling. Oncogene 2006; 25: 877-87.
6. Pioche-Durieu C, Keryer C, Souquere S et al. In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin. J Virol 2005; 79: 13 326-37.
7. Duncan RE, El-Sohemy A, Archer MC. Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity. J Biol Chem 2004; 279: 33 079-84.
8. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999; 285: 1028-32.
9. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001; 13: 555-62.
10. van Golen CM, Soules ME, Grauman AR, Feldman EL. N-Myc overexpression leads to decreased β1 integrin expression and increased apoptosis in human neuroblastoma cells. Oncogene 2003; 22: 2664-73.
11. Seales EC, Jurado GA, Brunson BA, Wakefield JK, Frost AR, Bellis SL. Hypersialylation of β1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res 2005; 65: 4645-52.
12. Sethi T, Rintoul RC, Moore SM et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999; 5: 662-8.
13. Brakebusch C, Bouvard D, Stanchi F, Sakai T, Fassler R. Integrins in invasive growth. J Clin Invest 2002; 109: 999-1006.
14. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA-Cancer J Clin 1999; 49: 33-64.
15. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA-Cancer J Clin 2001; 51: 15-36.
16. Greenberg JS, El-Naggar AK, Mo V, Roberts D, Myers JN. Disparity in pathologic and clinical lymph node staging in oral tongue carcinoma. Implication for therapeutic decision making. Cancer 2003; 98: 508-15.
17. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005; 11: 6924-32.
18. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005; 115: 959-68.
19. Clark EA, King WG, Brugge JS, Symons M, Hynes RO. Integrin-mediated signals regulated by members of the Rho family of GTPases. J Cell Biol 1998; 142: 573-86.
20. del Pozo MA, Price LS, Alderson NB, Ren XD, Schwartz MA. Adhesion to the extracellular matrix regulates the coupling of the small GTPase Rac to its effector PAK. EMBO J 2000; 19: 2008-14.
21. Manohar A, Shome SG, Lamar J et al. α3β1 integrin promotes keratinocyte cell survival through activation of a MEK/ERK signaling pathway. J Cell Sci 2004; 117: 4043-54.
22. 1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimension cultures and in vivo. Cancer Res 2006; 66: 1526-35.
23. Zhang H, Ozaki I, Mizuta T et al. β1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen-activated protein kinase dependent pathway. Cancer 2002; 95: 896-906.
24. Zhu Z, Sanchez-Sweatman O, Huang X et al. Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res 2001; 61: 1707-16.
25. Toutant M, Costa A, Studler JM, Kadare G, Carnaud M, Girault JA. Alternative splicing controls the mechanisms of FAK autophosphorylation. Mol Biol Cell 2002; 22: 7731-43.
26. Wen LP, Fahrni JA, Troie S, Guan JL, Orth K, Rosen GD. Cleavage of focal adhesion kinase by caspases during apoptosis. J Biol Chem 1997; 272: 26 056-61.
27. Lee SJ, Ha MJ, Lee J et al. Inhibition of the 3-hydroxy-3 methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21 (WAF1/CIP1) in human prostate carcinoma cells. J Biol Chem 1998; 273: 10 618-23.
28. 1-S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 1997; 272: 13-16.
29. Pruneri G, Pignataro L, Carboni N et al. Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer. J Clin Oncol 1999; 17: 3150-9.
30. Bao W, Thullberg M, Zhang H, Onischenko A, Stromblad S. Cell attachment to the extracellular matrix induces proteasomal degradation of p21 CIP1 via Cdc42/Rac1 signaling. Mol Cell Biol 2002; 22: 4587-97.
31. Mishima K, Inoue K, Hayashi Y. Overexpression of extracellular-signal regulated kinases on oral squamous cell carcinoma. Oral Oncol 2002; 38: 468-74.
32. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 2004; 64: 6461-8.
33. Roovers K, Davey G, Zhu X, Bottazzi ME, Assoian RK. α5β1 integrin controls cyclin D1 expression by sustaining mitogen-activated protein kinase activity in growth factor-treated cells. Mol Biol Cell 1999; 10: 3197-204.
34. Horiuchi A, Sumitomo M, Asakuma J, Asano T, Asano T, Hayakawa M. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res 2004; 10: 8648-55.
35. Kureishi Y, Luo Z, Shiojima I et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000: 6: 1004-10.
36. Paajarvi G, Roudier E, Crisby M, Hogberg J, Stenius U. HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage. FASEB J 2005; 19: 476-8.
37. Watanabe H, Pan ZQ, Schreiber-Agus N, Depinho RA, Hurwitz J, Xiong Y. Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57 KIP2 requires binding to proliferating cell nuclear antigen. Proc Natl Acad Sci USA 1998; 95: 1392-7.
38. Kim JS, Pirnia F, Choi YH et al. Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint. Oncogene 2000; 19: 6082-90.
39. Vincent L, Chen W, Hong L et al. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: Contribution to its anti-angiogenic effect. FEBS Lett 2001; 495: 159-66.
40. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-8.
41. Johnston PG, Mick R, Recant W et al. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 1997; 89: 308-13.
42. Shiga H, Heath EI, Rasmussen AA et al. Prognostic value of p53, glutathione S-transferase π, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 1999; 12: 4097-104.
43. Rahman L, Voeller D, Rahman M et al. Thymidylate synthase as an oncogene: A novel role for an essential DNA synthesis enzyme. Cancer Cell 2004; 5: 341-51.